Once a little-known entity, medical affairs is making its mark on the industry, and the timing couldn’t be better: Pharma portfolios are growing more scientifically complex and physicians want to have open, non-promotional dialogue with experts they can trust. The medical affairs function will play an increasing role in helping pharma companies to generate, interpret and communicate evidence.


As the medical affairs function becomes more valuable, there’s an opportunity to play a data-driven, collaborative role between development and commercial—and beyond. Managing Principal Pratap Khedkar recently spoke with colleagues Sarah Jarvis and Dean Hakanson to understand how the medical affairs department has advanced, and what it might look like in the future if it can overcome a few of the challenges standing in the way.